Please find attached.

IGL/SE/2026-27/39 14th August, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001 Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation for Q1FY27 Earnings Conference Call. Further to our letter bearing no. IGL/SE/2026-27/35 dated 6th August, 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, an investor presentation is attached for the information of the investors. This same is also being hosted on the Company’s website at www.indiaglycols.com. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a Investor Presentation Q1FY27 Safe Harbor Statement This presentation and the following discussion may contain “forward-looking statements” by India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of IGL about the business, industry and markets in which IGL operates. These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond IGL’s control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of IGL. In particular, such statements should not be regarded as a projection of future performance of IGL. It should be noted that the actual performance or achievements of IGL may vary significantly from such statements. Table of Contents 01 Proposed Restructuring 02 Q1 FY27 Financial Highlights 03 Business Overview Key Strengths 05 Annual Financial Highlights 06 Annexures Q1 FY27 Performance Highlights (Current Structure) Robust Performance Reflects Strength of Diversified Portfolio and Focused Execution IGL delivered a strong start to FY27 with double-digit growth in Gross Revenue, EBITDA and PAT, supported by a balanced portfolio and improving profitability Q1 FY27 Gross Revenue up + 19%, Net Revenue up + 9%, EBITDA up + 13%, and PAT up + 32% • Business portfolio remains well diversified, strengthening the premiumisation and margin enhancement journey • The spirits business recorded revenue of ₹ 361 Cr (+5.3% YoY) and EBITDA growth of 14.2% YoY. The company retained dominant market shares in UP and Uttarakhand while benefiting from premium product offerings and new product approvals • Chemicals revenue increased 20.6% YoY to ₹ 362 Cr, driven by Bio-Glycols, Green Solvents, and Performance Chemicals • BF reported revenue of ₹ 323 Cr, with EBIT rising 19% YoY to ₹ 27 Cr and EBIT margin at 8.4%. • EB reported its best-ever Q1, with revenue rising 65% YoY and EBITDA increasing 188% YoY. Growth was supported by new customer acquisitions, nutraceutical launches, nicotine business expansion, and improved operating efficiencies. • Finance Costs declined to ₹ 25 Cr in Q1FY27 from ₹ 45 Cr in Q1FY26, on account of debt reduction, supporting profitability growth • Debt levels reduced during the quarter, while the debt-to-equity ratio also improved. The company is also refinancing higher-cost borrowings with lower-cost debt to further improve financial efficiency • The proposed restructuring has received NCLT approval, with implementation activities progressing. The demerger is expected to create focused business entities and unlock value for shareholders over the medium term Proposed Restructuring Approved Demerger creates three focused platforms The NCLT sanctioned the Scheme of Arrangement on 17 July 2026. Upon effectiveness, the Spirits, Bio Fuel and Biopharma undertakings will transfer to dedicated resulting companies, while the remaining business continues within IGL India Glycols IGL Spirits Ennature Bio Limited Limited Pharma SEGREGATES Limited INTO Retained Businesses : Spirits Business Bio Pharma Business Chemicals PRE-DEMERGER Bio Polymers Business IMFL, Country Liquor Glycols India Glycols Bio-Fuel Business Limited Bio Glycols Integrated portfolio New Specialty Products BSPC • Potable Spirits • Bio Fuel • Ennature Industrial Gases Biopharma Already Listed on NSE & BSE To Be Listed on NSE & BSE To Be Listed on NSE & BSE FY26 Net Revenue ₹ 4,211 Cr Financial Performance – Q1 FY27 (New Structure) IGL Spirits Limited India Glycols Limited Ennature Bio Pharma Limited NET REVENUE NET REVENUE NET REVENUE ₹ 694 Cr ₹ 345 Cr ₹ 90 Cr (1% YoY) +24% YoY +53% YoY EBITDA EBITDA EBITDA EBITDA EBITDA EBITDA Margin% Margin% Margin% ₹ 120 Cr 17.3% ₹ 40 Cr 11.6% ₹ 10 Cr 11.1% +17% YoY vs 14.7% in Q1FY26 +12% YoY vs 14.7% in Q1FY26 +100% YoY vs 8.5% in Q1FY26 Q1FY27 Net Revenue EBITDA EBITDA Margin% Overall Performance ₹ 1,130 Cr ₹ 170 Cr 15.0% +9% YoY +13% YoY vs. 14.3% YoY in Q1FY26 IGL Spirits Limited – Q1FY27 IGL Spirits Spirits Business Bio Fuel Business NET REVENUE EBITDA Margin% ₹ 371 Cr * 22.9% +5% YoY +207 bps NET REVENUE IMFL ^ Non-IMFL ₹ 323 Cr (7% YoY) NET REVENUE NO. OF CASES NET REVENUE NO. OF CASES EBITDA Margin% ₹ 92 Cr 1.4 Mn ₹ 279 Cr 7.5 Mn 10.8% +26% YoY +55% YoY (1% YoY) +6% YoY +250 bps * Includes Other Operating Income ^ IMFL includes Prestige & Above, Regular and others 8 Business Outlook – IGL Spirits Limited 01 Accelerating IMFL Growth & Premiumization 04 Backward Integration Driving Cost Advantage IMFL volumes targeted to double through new brand launches, Captive high-quality ENA capacity, strategic raw material increasing contribution from higher-margin white spirits, and sourcing, and the planned malt plant provide supply security, expansion into premium categories and new brands with margin protection, product quality consistency, and sustainable strong pipeline; Strategic partnership with Amrut for bottling cost leadership; flexible manufacturing and multiple alcohol and marketing has strengthened the IMFL platform, positioning monetization routes the segment for sustained growth 02 Geographic & Channel Expansion 05 Market Leadership in Branded Non-IMFL Growth driven by deeper penetration in existing markets (UP, Strong leadership position led by Bunty Bubli, India's highest- Uttarakhand & Delhi), entry into new states such as Kerala, selling Non-IMFL brand, supported by strong market share, Andhra Pradesh, and Haryana, and enhanced focus on the superior gross margins, and industry-leading profitability; Defence/CSD channel with planned introduction of 3-4 new continuously maintaining strong market share in UP despite new brands entrants (from 4 to 20 players) and majority share in UK along with strong brand positioning & loyalty; Various accolades won from Limca Book of Records & Asia Book of Records 03 Strong Manufacturing Platform & Strategic Partnerships 06 Long-Term Value Creation with Disciplined Capital Long-standing Bacardi relationship, best-in-class Allocation manufacturing infrastructure, and dedicated production lines • Encouraging outlook for FY27, expecting to deliver EBITDA in with exclusive facility in the country for spirit maturation, excess of ₹ 500 Cr reinforce the company's position as a trusted partner for • Premium portfolio development through spirit maturation, leading global spirits companies continued brand-led growth, and a debt-free operating model underpin the company [Showing first 8,000 characters — download PDF for full document]